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Summary: A radioimniunoassay (RIA) for the measurement of thyroglobulin in human serum was developed
and factors that influence sensitivity were investigated. In a comparison of 3 different labeling procedures
(chloramine T, iodogen, lactoperoxidase) iodogen-prepared tracer proved to be slightly superior with respect
to sensitivity and stability.
The shelf life of the tracer was improved by a protein-enriched buffer, which serves äs a radical scavenger. The
binding kinetics of tracer to antibody at different temperature ranges were examined, and the most rapid and
complete binding was found at room temperature. For the preparation of Standard curves, several artificial
media were compared with thyroglobulin-free serum.
Second antibody Separation was investigated and optimized. By employing sequential Saturation, sensitivity of
0.75 g/l (Bö—3 SD) and 50% intercept of less than 5 g/l were achieved. The results of RIA measurements
of thyroglobulin in 142 patients with papillary and follicular thyroid carcinoma after thyroidectomy and 131I
treatment were compared with 131I whole-body scans. The results confirmed that serum thyroglobulin is an
early indicator of recurrency.
Radioimmunoassay für Thyreoglobulin im Serum zur Früherkennung von Rezidiven und Metastasen in der
Nachsorge von Patienten mit differenzierten Schilddrüsenkarzinomen
Zusammenfassung: Es wurde ein Radioimmunoassay (RIA) zur Messung von Human-Thyreoglobulin im
Serum entwickelt und die Faktoren untersuch^ die die Empfindlichkeit des Nachweises beeinflussen. Von
den Markierungsmethoden mit Chloramin T, iodogen und Lactoperoxidase zeigte der mit Iodogen gewon-
nene Tracer die höchste Empfindlichkeit und Stabilität.
Eine Untersuchung zur Aufbewahrung der Tracer zeigte, daß mit einer pröteinreichen Lösung als Radikal-
Fänger die Haltbarkeit der Tracer gesteigert wird. Die Kinetik der Bindung von Tracer an Antiserum bei
verschiedenen Temperaturen ergab die schnellste Assoziation bei Raumtemperatur, sowie auch das höchste
Ausmaß an Bindung in diesem Temperaturbereich. Verschiedene künstliche thyreoglobulinfreie Medien
wurden untersucht und ihr Einsatz als Verdünnungsmedien für die Standardreihe geprüft.
Die Doppelantikörpertrennung wurde optimiert. Es resultierte eine Empfindlichkeit des Nachweises von 0,75
/^1 (B0-3 SD) und ein 50% Intercept unter 5 g/I.
Die Resultate des RIA für Thyreoglobulin bei 142 Nachsorge-Patienten mit papillärem und follikulärem
Schilddrüsenkarzinom (Zustand nach Thyreöidektomie und 131I-Behandlung) wurden mit denen der 13II-
Ganzkörperszintigraphie verglichen. Hierbei bestätigte sich die Bedeutung der Bestimmung von Thyreoglo-
bulin als Frühindikator für das Vorliegen eines Rezidivs.
*) Supported by IOE (Tumorzentrum Heidelberg/Mannheim).
J. Clin. Ohem. Clin. Biochem. / Vol. 22, 1984 / No. 10
662 Falk, Schmidt-Gayk and H fncr: Serum thyroglobuiin in thyroid carcinoma
Introduction
Scveral methods have been published for the thyro-
globuiin assay (1—4). Radioimmunoassay has found
wide application, and most assays employ the double
antibody procedure.
For clinical use of the thyroglobuiin assay, sensitivity
and precision seem to be most important (5, 6). The
assay is mainly employed in the follow-up of patients
with differentiated thyroid carcinoma to detect early
metastases and recurrencies.
I 3 II scans in connection with the measurement of se-
rum thyroglobulin proved to be most reliable in the
follow-up of those patients (7—11). Some authors
(6, 12—14), have even proposed a reduction of scan-
ning frequency after treatment if regul r thyroglobu-
iin measurements are performed. Since patients, af-
ter successful therapy of papillary and follicular thy-
roid carcinoma, should have no thyroglobulin in the
serum (1,5, 8v9), the occurrence of metastases and
recurrencies may be detected earlier by sensitive as-
says (5).
Therefore, our aim was to study the factors impor-
tant for the sensitivity of thyroglobulin RIA. Fur-
thermore we wanted to show the advantages of thy-
roglobulin RIA in the follow-up of thyroid carcino-
ma. Patients with elevated serum thyroglobulin lev-
els but no clinical evidence ( I 3 II scan, ehest X-ray,
palpation) of relapse were especially checked with a
view to explaining the nature of the elevated thyro-
globulin values.
Materials and Methods
Reagen t s
Human thyroglobulin was isolated from thyroid glands obtained
at surgery and the purification was performed s previously de-
scribed (4).
For the preparation of Standards and for labeling, thyroglobulin
was diluted in phosphate buffer, pH 7.4.
Other reagents (analytical grade, "pro analyse") were purchased
from Merck AG, Darmstadt, FRG. I25I was from Amersham
Buchler GmbH, Braunschweig, FRG. Human serum albumin was
from Behringwerke AG, Marburg/Lahn, FRG. All assays were
performed in RIA-vials purchased from W. Sarstedt, N mbrecht,
FRG.
Preparat ion of an t i se rum
Antisera to thyroglobulin were prepared in rabbits injected at 4—
8 week intervals over a total of 12 months. A suitable antiserum
with a high titer was obtained in rabbit no. l.
The antiserum was used at a dilution of 40,000-fold with phos-
phate buffer (0.06 mol/1, pH 7.4) containing human serum albu-
min (l g/l), sodium azide (l g/l) and EDTA (Titriplex III, 0.4 g/l)
s diluent (working dilution). In addition, antiserum was pur-
chased from UCB, Br ssel, Belgium.
l o d i n a t i o n o f t h y r o g l o b u l i n
Chloramine T method
Thyroglobulin was iodinated according to a modification of the
method by Greenwood & Munter (15):
20 μg of purified thyroglobulin, 18.5 MBqof I25I (IMS 30, Amer-
sham Buchler) and 10 μΐ of a lg/1 solution of chloramine T and
10 μΐ of phosphate buffer pH 7.4,0.5 mol/1 were mixed and react-
ed for 60 s. Then 50 μΐ of sodium metabisulfite (2.5 g/l) were
added, immediately followed by ΙΟΟμΙ of dextran blue Mr
200000 (10 g/l) and the mixture was applied on a Sephadex G25
column (0.9 cm x 30 cm) and eluted with a Tris/HCl/albumin
buffer, pH 7.4. Fractions (20 drops) were collected in a LKB 7000
fraction collector, and chromatography was complete after col-
lecting 40 ffactions. The first peak of radioactivity containing 125I
thyroglobulin was pooled.
For convenience, and without alterations in the results, this co-
lumn was replaced by a ready to use column (Pharmacia PD 10,
Pharmacia GmbH, Freiburg, FRG) and elution was performed
with Tris-HCl-buffer, pH 7.4, containing 50 mg/1 of human serurn
albumin. A fraction collector is not necessary.
Routinely, the tracer was diluted in the phosphate buffer used for
diluting antiserum (1300 Bq/100 μ!).
Lactoperoxidase method
The lactoproxidase method for iodination was employed accord-
ing to the procedure given by ΒΙΟ-RAD, Munich, FRG. The
same amounts of thyroglobulin and iodine were used.
lodogen method
Labeling by use of iodogen was performed according to Wood
(16). lodogen (2 μg, purchased from Pierce, Eurpchemie B V,
Rotterdam, NL) was dissolved in dichloromethane and pl ced in
Eppendorf reaction vials. The dichloromethane was evaporated
by N2 and the tubes stored at -20 °C. lodination was performed
with the same amounts of thyroglobulin and 125I s described
above. Incubation was carried out at room temperature for 10 min
with constant mixing on an automatic mixing device. All iodina-
tions were done under a well ventilated hood.
.··-' :···· *
Second an t ibody Separat ion
Second antibody (RD 17, anti-rabbit IgG from donkey) was from
Deutsche Wellcome, Burgwedel, FRG. This second antibody was
diluted 1:24 in the buffer, used for diluting first antibody.
R a d i o i m m u n o a s s a y
Before radioimmunoassay, all samples were screened for interfer-
ing anti-thyroglobulin autoantibodies (2, 9, 17, 18). Assay tubes
and Standards were arranged in duplicate and 200 μΐ of Standards,
controls and unknowns were added to the appropriate tubes, foU
lowed by 100 μΐ of thyroglobulin antiserum (Ist antibody). The
tubes were mixed, incubated s indicated (routinely 48 h), then
100 μΐ (1300 Bq) of I25I labeled thyroglobulin was added to all
tubes. Again the tubes were mixed and incubated for 48 h at room
temperature. Then 100 μΐ of second antibody (donkey anti-rabbit
IgG, RD 17, Deutsche Wellcome GmbH) was added and incuba-
tion continued for 2 h. The tubes were centrifuged for 10 min at
2000 g, at 4 °C to separate the bound and free fractions. The su-
pernate was aspirated and disearded. The Sediment was washed
with 600 μΐ of washing solution (9 g/l NaCl). Again the tubes were
centrifuged for 10 min at 2000 g and the supernates again aspirat-
ed and disearded. The radioactivity of the sediment was counted
for l min or until 10000 counts were accumulated. The nonspecif-
ic counts (average of one duplicate in each assay) were subtracted
from the average of each duplicate determination of sample and
Standard. The Standard curve was constrveted by plotting the 1|251
labeled thyroglobulin versus the conceritration of Standards on 3-
cycle semilogarithmic paper s shown in the figures.
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Methodological results
l o d i n a t i o n
The use of different labelling procedures resulted in
high incorporation of I25I with the chloramine T and
the iodogen method and only low incorporation us-
ing the lactoperoxidase method. With iodogen and
chloramine T, 83% of 125I was incorporated into thy-
roglobulin and 45% with lactoperoxidase. Specific
activities of 370—740 kBq^g were obtained.
B i n d i n g k ine t ics
The influence of time on the binding of 125I labeled
thyroglobulin tracer to the antiserum is illustrated in
figure 1.
As shown in figure l, iodogen-derived tracer result-
ed in better binding to the antiserum.
The binding of the tracer to the antibody is also in-
fluenced by temperature. Therefore, association ki-
netics were performed at 4—8°C (refrigerator),
room temperature, 37 °C and 42 °C (fig. 2).
As indicated in figure 2, incubation at room temper-
ature resulted in the rnost rapid binding of tracer to
the antibody. After 48 h, binding is nearly complete.
Comparison of the binding kinetics of figure 2 with
those of figure l shows that tracers prepared by the
iodogen method display the same binding kinetics.
From these experiments it was decided to perform
all further experiments at room temperature.
Tab. 1. Influence of labelling method and storage on binding of
125I labeled thyroglobulin.
Days Total activity B
after
label· ( q/ΙΟΟμΙ
in
 tracer)
Iodogen
1 1301.5
7
14 1095.2
21- 1018.6
28 909.7
Δ = 391.8
Chloramine T
1 1360.5
7 1244.9
14 1126.0
28 1043.3
Δ = 317.2
(Bq)
733.8
576.6
495.9
419.8
329.6
Δ = 404.2
613.3
512.6
461.5
352.0
Δ = 261,3
Bo/T
0.56
-=
0.45
0.41
0.36
Δ = 0.20
0.45
0.41
0.41
0.34
Δ = 0.11
Non-specific
binding
Bq
35.7
28.5
30.9
31.5
27.8
34.2
34.7
35.2
40.2
(% of
B )
4.9
4.9
6.2
7.5
8.4
Δ = 3.5
5.6
6.8
7.6
11.4
Δ = 5.8
B = toinding of thyroglobulin Standard
T = total activity
Δ = difference
10 20 30 £0 50 60 70 80 90 100 110
t [h]
Fig. 1. Saturation kinetics at room temperature for I25I thyro-
globulin labeled according to the iodogen (Δ and O) and
lactoperoxidase (D) method.
In addition, binding of iodogen derived tracer to commer-
cially available antiserum ( , UCB, Belgium) and to
our antiserum ( ) is shown.
10 20 30 40
t lhj
50 60 70
Fig. 2. Binding of I25I thyroglobulin (labeled by lactoperoxidase)
to the antibody at different temperature ranges:
B = 4-8 °C, C = room temperature, A = 37 °C and V =
42 °C.
Tracer s tabi l i ty
The labeling method influenced both the shelf life of
the tracer and the unspecific binding. The influence
of storage on the results is demonstrated in table l.
The storage medium is of influence on the shelf life
of the tracer. Protein is generally regarded s a radi-
cal scavenger. Storage of the tracer was therefore de-
termined in routine buffer used for diluting antibo-
dies and in a protein enriched buffer containing 10
g/1 human serurn albumin (tab. 2).
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Tab. 2. Storage of I25I thyroglobulin in phosphate buffer (0.06
mol/I, pH 7.4, containing I g/l human serum albumin,
l g/l NaN-ι and 0.4 g/l EDTA) and in a protein-enriched
buffer containing 10 g/l human scrum albumin. These da-
ta were obtained 16 days after labcling.
Sample lodogen derived tracer lodogen derived tracer
with 10 g/l human with l g/l human
serum albumin serum albumin
NSB
B
1P-50%
24.3 Bq (5.3%)
456.5 Bq
5.0 ng/1
36.0 Bq (7.7%)
470.2 Bq
6.2 ng/1
NSB = non-specific binding
B = binding of thyroglobulin Standard
1P-50% = 50% intercept point
It is evident from table 2 that both the unspecific
binding and the 50% intercept are lower in the pro-
tein enriched\ buffer. The use of different tracers re-
sulted in different sensitivities (fig. 3).
Figure 3 indicates that the most sensitive tracer was
obtained by the iodogen method, resulting in 50%
intercepts from 3 μg/l - 5 μg/l.
Thyroglobul in Standards
Since it is difficult to obtain sufficient amounts of
thyroglobulin-free serum, several artificial media
were checked for their suitability s thyroglobulin
Standard diluents (tab. 3).
Tab. 3. Binding of I251 thyroglobulin to antiserum in different
Standard media.
Sample Bq Bqof % %
NSB Sample NSB
Human thyroglobulin standard-0
in bovine serum
Protein/phosphate buffer with
sodium-azide and EDTA-Na2
• r
572.9 82.7 100.0 14.4
Human serum albumin
Human serum albumin
Human serum albumin
Human serum albumin
Patient C.+
lg/1
10 g/l
20 g/l
40 g/l
611.0
576.7
582.3
586.5
581.4
45,1
23.8
20.2
13.0
10.0
106.7
100.7
101.6
102.4
101.5
7.9
4,2
3.5
2.3
1.7
NSB = non-specific binding
+
 = patient C. is thyroidectomized with no signs of recurrence
for more than two years after Operation for medullary thy-
roid carcinoma
As shown in table 3, a phosphate b ffer (0.06 mol/1,
pH 7.4) containing 10 g/1 human serum albumin, l
g/l NaN3 and 0.4 g/l EDTA yielded a count rate very
near to that observed for thyroidectomized patient
"C", a patient with previous medullary thyroid carci-
noma, followed by more than 2 years free from the
disease. Buffer compositions containing higher con-
centrations of human serum albumin (20 g/l or 40 /l)
may be used, but this becomes more expensive.
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Fig. 3. Sensitwity of the assay determined by the 50% intercept point. Tracer was prepared by the lactoperoxidase, iodogen and chlor-
amme T methods. Additionally the influence of antiserum dilution (Γ antibody) on sensitivity, s well s different incubation
modes (O = 3 + 3 days, · = 2 + 2 days, A = l 4- l day) are shown.
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The medium for the Standard influenced the shape of
the Standard curve. Thyroglobulin was therefore dil-
uted in thyroglobulin-free serum and in the above
mentioned buffer (10 g/l human serum albumin).
The results are illustrated in figure 4.
As seen from figure 4, the Standard curves are essen-
tially superimposable.
Sensi t ivi ty and mode of incubat ion
Radioimmunoassays may be performed at equilibri-
um or with sequential Saturation. For the purpose of
detecting low concentrations of thyroglobulin in se-
rum, different modes of incubation were compared
. 5).
It is apparent from figure 5 that sequential Saturation
results in increased sensitivity. 90% of the tracer is
bound at l μg/l, about 80% at 2 μg/I and about 20%
at 20 μg/l.
Separation of bound and free l igand
Separation of bound and free I25I thyroglobulin
(tracer) was performed by a double-antibody System
(donkey anti-rabbit IgG, RD 17, from Deutsche
Wellcome GmbH).
10000Ί-400
1 2 4 θ 16 3? 64
Thyroglobulin [/ig/l]
Fig. 4. Dilution of Standards in thyroglobulin-free serum (Φ, pool
from totally thyroidectomized patients) and in phosphate
buffer with protein, 10 g/l, sodium-azide and EDTA (·).
1.00
0.90
Ο.ΘΟ
0.70
0.60
o.5o
0.40
0.30
0.20
0.10
: Non-speqific binding
2 4 8 16
Thyroglobulin Ιμς/Ι]
32 64
Fig. 5. Displacement of 125I thyroglobulin (y-axis) by unlabeled
thyroglobulin (x-axis). Incubation was performed at equi-
librium with 48 h ( ) and 72 h (Δ) at room temperature
and with 96 h (D) at 4-8 °C. Additionally sequential satu-
ration is demonstrated with 2 days incubation of Standards
with antiserum and another 2 days with 125I-thyroglobulin
added (Δ).
Second antibody Separation in all assays was performed at
room temperature. Values of nonspecific binding (NSB)
are shown below the dotted line.
It was necessary to first optimize the amount of nor-
mal rabbit serum included in the antiserum dilution.
The second antibody (anti-rabbit IgG) was diluted
1:24. A precipitation experiment with 125I thyro-
globulin and increasing amounts of first antibody
containing normal rabbit serum (4 or 6 ml/l) was
performed (fig. 6).
The addition of normal rabbit serum (6 ml/l) to the
first antibody resulted in extremely high coefficients
of Variation (fig. 6), when 100 μΐ first antibody and
100 μΐ second antibody were used.
On the other hand, when 4 ml/l normal rabbit serum
were added to the first antibody, and 100 μΐ first
antibody and 100 μΐ second antibody were em-
ployed, a plateau of precipitated counts could be ob-
served. Therefore, for further experiments 4 ml nor-
mal rabbit serum per liter first antibody solution
were used.
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10 20 30 40 50 60 70 80 90 100 110
First antibody [μ\]
Fig. 6. Precipitation experiment with I25I thyroglobulin and dif-
ferent amounts of first antibody containing normal rabbit
serum (4 ml/l, Δ or 6 ml/l, O).
The tube contained 200 μΐ thyroglob lin-free medium,
100 μΐ Ι25Ι thyroglobulin (1300 Bq), 10-110 μΐ first anti-
body, and was incubated for 48 h at room temperature.
Then 100 μΐ second antibody from donkey (1:24, pur-
chased from Deutsche Wellcome GmbH) was added and
incubation continued for another 2 h. All tubes were filled
to 510 μΐ with Standard phosphate buffer. (0.06 mol/1,
pH 7,4, containing l g/l human serum albumin, l g/I NaN·*
and 0.4 g/l EDTA).
As second antibody precipitation might be influ-
enced by the incubation temperature, different
temperature ranges and incubation periods were in-
vestigated (fig. 7).
It is evident from figure 7, that 2 h of incubation at
room temperature was optimal.
Wash ing
After second antibody Separation, some laboratories
wash the precipitate. The effect of washing on_ the
second antibody Separation was investigated (fig. 8).
As can be seen from figure 8, washing with 600 μΐ of
9 g/l NaCl solution reduces nonspecific binding and
alters the shape of Standard curve at higher concen-
trations of unlabeled thyroglobulin. Therefore,
washing was performed in further experiments be-
cause high nonspecific binding increases the impreci-
sion of the results.
£- 2
A
t [h]
Fig. 7. Precipitation of 125I thyroglobulin by second antibody
from donkey (1:24, purchased from Deutsche Wellcome
GmbH) at different temperature ranges: A = 4—8 °C (re-
figerator), 9 = room temperature and Δ = 42 °G.
2 U 8 16
Thyroglobulin [jj,g/IJ 32
Fig. 8. Effect of washing (A) and not-washing (0) the second
antibody precipitate on the shape of Standard curve. In
e ch case nonspecific counts were subtracted.
Quality control
Parallelism
A serial dilution was made of 2 patient sera contain^·
ing thyroglobulin of about 30 μg/l. Jhyroglobmlin-
free serum was used s diluent. The 2 curves plotted
s a function of the dilution display par llelism to the
Standard curve (fig. 9).
However, some discrepancies exist in the high con-
centration r nge above 32
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Dilut ion
1/32 1/16 1/Θ 1M 1/2 1/1
Patient
no 4053i
no 4106
Standard
curve
1 2 4 θ 16 32
Thyroglobulin lμgl(} 64
Fig. 9. Displacement of I25I thyroglobulin from the antiserum by
thyroglobulin-standards (O) and by dilution of paticnt se-
ra (Q and A). Patient sera were diluted in thyroglobulin-
free human scrum. Standards werc diluted in phosphate
buffer containing serum albumin, 10 g/I, sodium azide and
EDTA.
Recovery
An increasing amount of thyroglobulin was added to
three serum samples with different thyroglobulin
concentrations (fig. 10).
Figure 10 reveals that recovery is slightly higher than
100%.
Imprecision
Radioimmunoassays are known for their different
precision at different concentrations of unlabeled li-
gand. For that reason, a precision profile was deter-
mined. The RIA was performed s usual (2d -f 2d +
2h at room temperature). For each Standard concen-
tration, 12 ineasurements were performed. A typical
U-shaped precision profile was obtained with eoeffi-
cients of Variation between 9% (l ^g/l), 3% (4 μg/l)
and 5% (64 μg/l). The Standard deviation is less than
0.2 μξ/l
Reference
30 healthy individuals 20-40 years of age exhibited
serum thyroglobulin levels demonstrated in figure 11.
5 10 15
Thyroglobulin added
20
Fig. 10. Thyroglobulin was added to 3 different normal human
sera (A, O and O). The amount of thyroglobulin added is
shown on the x-axis, and the thyroglobulin recovcred on
the y-axis.
90
80
70
•60
l"
30
20
10
30
Healthy
individuals
Fig. 11. Thyroglobulin serum concentration in 30 healthy indi-
viduals aged 20—40 years.
Sens i t i v i ty
The sensitivity of the thyroglobulin RIA was evalu-
ated using the usual statistical test: 11 measurements
of the radioactivity of the bound fraction were ob-
tained for the Standard without any detectable thyro-
globulin. The mcan, the Standard deviation and the
coefficient of Variation were then calculatcd. The
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. l
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minimum detectable concentration of thyroglobülin
was then read off the Standard curve äs mean counts
at zero concentration minus 3 Standard deviations.
This gave a sensitivity of 0.75 g/l. RIA for this
experiment was performed äs usual: 2d + 2d + 2h at
room temperature.
In terassay coef f ic ien t of Var ia t ion
A control serum containing about 2.5 g/l of thyro-
globülin was determined in 8 consecutively per-
formed assays. An interassay Variation coefficient of
7.8% was obtained.
Clinical results
Patients
140 patients with papillary or follicular thyroid carci-
noma and 2 patients with anaplastic thyroid carcino-
ma were selected in order to compare thyroglobülin
radioimmunoassay with 131I total body scans. Pa-
tients were only included if at least l scan and simul-
taneous serum sample without interfering antithyro-
globulin autoantibodies were available.
All patients had undergone thyroidectomy äs well äs
131I therapy and showed no residual thyroid tissue.
There were 107 females and 35 males and mean age
was 49.6 ± 13.8 years.
In 109 patients, clinical and radiological (ehest X-
ray, 131I total body scan) investigation presented no
signs of local or distant recurrence. 7 patients
showed local relapse and 26 distant metastases.
Thyroglobül in rad io immunoassay and 131I
total body scan (tab.4)
As indicated in table 4, thyroglobülin RIA was su-
perior to I31I total body scan in 3 of 7 cases with local
recurrence and in 9 of 26 patients with distant me-
tastases. In contrast I31I total body scan was superior
to thyroglobülin RIA in 2 of 26 patients with distant
metastases.
Of 109 patients without evidence of relapse by clini-
cal and radiological (ehest X-rayfand 13II total body
scan) investigation, 17 showed elevated thyroglobü-
lin serum levels (>6.4 g/l).
Discussion
For the labeling of thyroglobülin, most äuthors use
the chloramine T method (1-^3,19,20). In addition,
the lactoperoxidase method (17, 19, 21, 22) and the
iodogen technique (23, 24) are enaployed. Accord-
ing to our data, the iodogen labeling procedure was
slightly superior to chloramine T and lactoperoxi-
dase; satisfactory 125I incorporation, high specific ac-
tivity and low nonspecific binding were obtained.
The lactoperoxidase technique Was relatively ineffi-
cient. The low incorporation of 125I into thyroglobü-
lin by this method may be explained by the fact that
some of the radioactive iodine was incorpof ated into
the enzyme.
In contrast to our findings, Schlumberger & van Her-
le (19) reported that lactoperoxidase-labeled tracers
yielded higher binding and more prölonged stability
than chloramine T tracers. The storage of the tracer
was improved by using a protein-enriched buffer
serving äs tracer dilüent (10 g human serum albumin
per l tracer solution) and radical scavenger.
v ' .. .
Schlumberger & van Herle (19) and others (21, 25)
stipulated that 125I labeled thyroglobülin should be
rechromatographed weekly on a Sephädex G200 co-
lumn. Our data, however, suggest that weekly re-
chromatography is not necessary. Iodogen derived
tracer for example mäy be used for more than 4
weeks with no need for rechromatography. This dis-
agreement with our data may be explained by the
very high ratio of 125I to thyroglobülin used by
Tab. 4. Thyroglobulin radioimmunoassay and ml total body scan findings in the follow-up of 142 patients with thyroid carcinoma.
Disease state in the follow-up of 142 patients HTg-RIA
with thyroid carcinoma ' 3 l I scan ®
No signs of local recurrence or distant metastases —
- Local recurrence 4
Distant metastases 13
HTg-RIA®
131Iscan©
17
3
9
HTg-RIA HTg-RIA
mlscan® 131Iscan©
92
2 2
HTg-RIA = serum thyroglobulin above the critical level of 6.4 g/l
HTg-RIA = serum thyroglobulin below the critical level of 6.4 g/l
I31I scan = positive I31I total body scan in the follow-up
 %,'
I 3 II scan 0 = negative 13II total body scan in the follow-up
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Schlumberger & van Herle (19): 74 MBq 125I and
only 5 μ§ thyroglobulin were used together with
heavy oxidation of the protein (25 μg chloramine T
oxidizing for 90 s).
Our iodinations were all performed with a ratio of
125I to thyroglobulin which is 16-fold lower (18.5
MBq 125I and 20 μg thyroglobulin). Using the chlor-
amine T method, we only employ 10 μg chloramine
T and oxidation was stopped after 60 s. For prepara-
tion of the Standard curve, bovine serum should not
be used s Standard diluent, because it gives rise to
high non-specific binding (14%).
Human serum devoid of thyroglobulin is the best
Standard diluent, though it is difficult to obtain a suf-
ficiently large pool. Therefore, different buffers were
tested s substitute. A phosphate buffer with protein
(human serum albumin, 10 g/l), sodium azide and
EDTA yielded very similar binding and non-specific
binding results compared with thyroglobulin-free se-
rum (fig. 5). Bodlaender et al. (2) also employ phos-
phate-buffered saline solution (73 g/l bovme serum
albumin) for preparation of Standard curve.
Sequential Saturation for the radioimmunoassay of
thyroglobulin is mostly used (2, 3,21, 26). However,
the reported incubation periods are much shorter (2,
3, 26, 27).
An attempt was also made to determine the optimal
incubation temperature. From several experiments
(fig. 2, 5, 7) i t was decided to perform all incubation
Steps at room temperature. Some authors, however,
incubate (first and second incubation) at 4°C (3,
21), others at 37 °C and 25 °C, respectively (2, 27),
or 37 °C and room temperature, respectively (26).
As diagrams of binding kinetics have not been pub-
lished by these authors, improved sensitivity may be
obtained by prolongirig the first and second incuba-
tion period and by determiriation of the correct incu-
bation temperature. In our assay, we use 2 days + 2
days at room temperature, It is evident from this
evahiation that every double antibody System con-
sisting of antiserum, carrief γ-globulin and second
antibody has to be checked carefully s far s dilu-
ti h of antiserunij eoncentration of carrier γ-globulin
and incubation temperature are concerned. Satisfac-
tory results were obtained by adding 4ml normal
r bbit serum to 11 of the first antibody solution (an-
tiserum 1:40000). The necessary incubation time for
second antibody from donkey (purchased by
Deutsche Wellcome GmbH, diluted 1:24) was only
2 h at room tefnperature. In contrast to our findings,
Benita et al. (3) reported that by use of second anti-
body from donkey an incubation period of 16—20 h
is required (incubation temperature not mentioned).
There was parallelism between dilutions of the Stan-
dards and of patient sera using thyroglobulin-free se-
rum s diluent. The recovery of added thyroglobulin
was nearly 100% at concentrations ranging from
2 μg/l to 10 μg/l and slightly above 100% at higher
concentrations.
The accuracy in the high concentration r nge (16
μg/l - 64 μg/l) depended on washing the precipitate
after second antibody Separation. According to van
Herle et al. (1) washing the precipitate is not neces-
sary. This discrepancy may be due to the different
assay volumes used.
The precision profile of our assay is typically U-
shaped, s is usual for radioimmunoassays.
Intraassay coefficient of Variation ranged from 3%
to 9%. The interassay coefficient of Variation for a
patient sample (thyroglobulin: 2.5 μ§/1) was 7.8%.
With the usual mode of incubation (2d + 2d + 2h at
room temperature) a sensitivity of the assay of 0.75
μg/l was achfeved, and the 50% intercept ranged
from 4 μg/l to 7 μg/l (antiserum 1:40000, labeling
method: iodogen or chloramine T, incubation peri-
ods s usual). These findings contrast with the data
previously published (tab. 5).
Tab. 5. Sensitivity of published thyroglobulin radioimmunoas-
says s determined by 50% intercept point.
Author
Van Herle et al.
V 'an Herle &. Oller
Bodlaender et al.
Gembicki et al.
Benilatlal.
Schlumberger & Van Herle
Year
1973
1975
1978
1981
1981
1982
50% inter- Refer-
cept-point ences
of thyro-
globulin
ΚΙΑ(μδ/1)
30.0 (1)
27.0 (29)
45.0 (2)
65.0 (28)
100.0 (3)
25.0 (19)
The reference r nge is in accordance with the litera-
ture (8, 30). However, lower normal human thyro-
globulin ranges have been reported (13, 17, 21).
For discrimination of patients in remission and those
presenting local or distant metastases, a critical level
(cut-off) of 6.4 μg/l was determined by statistical
means (31).
Definite evidence of local recurrence in our 7 pa-
tients was lways associated with elevated thyroglob-
ulin serum levels (>6.4 μg/l). In 3 of these 7 instan-
ces the 131I total body scans, however, were negative.
J. Clin. Chem. Clim Biochem. / Vol. 22, 1984 / No. 10
670 Falk, Schmidt-Gayk and Hüfner: Serum thyroglobulin in thyroid carcinoma
In 26 subjects with distant metastases, high serum
thyroglobulin levels and positive I31I scans were
found in 13 (50%) cases. In 9 patients (34%) with
elevated serum thyroglobulin the I31I scans were
negative. In 2 examinations (8%), positive 131I scans
were associated with thyroglobulin levels lower than
6.4 g/l. An additional 2 subjects (8%) showed both
negative I31I scans and low serum thyroglobulin
values (<6.4 g/l).
Thus in 12 of 14 cases (86%) with negative 131I scin-
tigrams and definite recurrent thyroid carcinoma,
the diagnosis was verified by the measurement of
thyroglobulin.
In 92 of 109 patients (84%) presenting no clinical
evidence of relapse, both serum thyroglobulin and
131I scans were negative. However, in 17 of these 109
subjects elevated serum thyroglobulin levels were
found. In contrast to other tumour marker tests we
do not regard
 vthese elevated thyroglobulin levels äs
"false positive". According to our experience these
patients represent a "high risk group" since 2 of
these 17 subjects have since revealed recurrent thy-
roid carcinoma.
These findings suggest that a sensitive thyroglobulin
radioimmunoassay is able to predict a relapse of thy-
roid carcinoma at a time when all other clinical data
are still inconspicuous. Stimmarizing all the results,
we can postulate:
1. Serum thyroglobulin is a very reliable and eafly
indicator of recurrency.
2. Sensitive thyroglobulin radioimmunoassay helps
to reduce the number öf 131I contfol scans, espe^
cially since Hüfner et al. (32) have demonstfäted
that routine 13II scan is of very low efficiency.
3. With the help of thyroglobtiiin assay we can pick
out "high risk patients". Those patients present-
ing elevated serum thyroglobulin values (after
thyroidectomy and 131I therapy) but no further
clinical evidence of relapse should be subjected to
close and detailed screening.
4. However, in those cases where thyroglobulin au-
toantibodies are present, our thyroglobulin ra-
dioimmunoassay is not usable.
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